C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

OBJECTIVE: On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors produce additional LDL-C lowering, r...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Prev Cardiol
Main Authors: Nelson, Adam J., Puri, Rishi, Brennan, Danielle M., Anderson, Todd J., Cho, Leslie, Ballantyne, Christie M., Kastelein, John JP., Koenig, Wolfgang, Kassahun, Helina, Somaratne, Ransi M., Wasserman, Scott M., Nissen, Steven E., Nicholls, Stephen J.
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2020
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8315612/
https://ncbi.nlm.nih.gov/pubmed/34327467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajpc.2020.100091
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker